Result of AGM

RNS Number : 0323K

SkinBioTherapeutics PLC

29 December 2020

 

29 December 2020

SkinBioTherapeutics plc

Results of AGM

SkinBioTherapeutics plc's (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

Resolution		For & Discretionary		Against		Withheld
		Number of votes	%	Number of votes	%	Number of votes
01	Ordinary resolution to receive and adopt the 2020 Financial Statements	56,163,552	100.00%	Nil	0.00%	Nil
02	Ordinary resolution to re-appoint Jeffreys Henry as auditors	56,163,552	100.00%	Nil	0.00%	Nil
03	Ordinary resolution to re-elect Stuart Ashman as a director	56,140,652	99.96%	22,900	0.04%	Nil
04	Ordinary resolution to re-elect Martin Hunt as a director	56,140,652	99.96%	22,900	0.04%	Nil
05	Ordinary resolution to re-elect Dr Cathy Prescott as a director	56,163,552	100.00%	Nil	0.00%	Nil
06	Ordinary resolution to re-elect Doug Quinn as a director	56,140,652	99.96%	22,900	0.04%	Nil
07	Ordinary resolution to authorise the directors to allot shares	56,107,097	99.90%	22,900	0.04%	33,555
08	Special resolution to authorise the directors to disapply pre-emption rights	55,896,449	99.52%	37,294	0.07%	229,809
09	Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment	55,897,801	99.53%	35,942	0.06%	229,809

For more information please contact:

SkinBioTherapeutics plc	Tel: [phone]
Stuart Ashman, CEO Doug Quinn, CFO
Cenkos Securities plc (Nominated Adviser & Broker)	Tel: [phone]
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales)
Instinctif Partners	Tel: [phone]
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	[e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotherapeutics.com .

 

END

 

 

RAGKKCBPBBDDOBB